Bipartisan Policy Center regenerative medicine

The backstory on my opinion piece in SF Chronicle critical of CIRM lobbying

CIRM-2.0

Today an opinion piece that I wrote about CIRM was published in the San Francisco Chronicle. The unusual element here is that the article is critical of CIRM. More specifically I raised concerns about a recent political trend at CIRM under its new President Randy Mills lobbying for dramatically weaker stem cell regulatory oversight. The Chronicle piece was first posted …

The backstory on my opinion piece in SF Chronicle critical of CIRM lobbying Read More »

Huge clinical trial patient fees allowed by FDA at times, details often secret

Monopoly1-300x2851

I am often critical of for-profit stem cell clinics on this blog for numerous reasons. For instance, one thing that concerns me greatly about these clinics is that they charge patients to get experimental “treatments” that have not been proven to be safe or effective. But as some patients have pointed out to me over the …

Huge clinical trial patient fees allowed by FDA at times, details often secret Read More »

Alliance for Regenerative Medicine (ARM) Opposes REGROW Act, Risks to Patients Cited

Alliance-for-Regenerative-Medicine

The biggest debate today in the stem cell world is over how much regulation is needed for new, investigational stem cell therapies that are not as yet approved. Sometimes it feels very lonely being out there publicly advocating for appropriately thorough regulation of stem cell therapies and at times I get a lot of heat for …

Alliance for Regenerative Medicine (ARM) Opposes REGROW Act, Risks to Patients Cited Read More »